These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3091433)

  • 1. Class 1/3 outer membrane protein vaccine against group B, type 15, subtype 16 meningococci.
    Poolman JT; Beuvery EC; Hopman CT; Witvliet MH; Timmermans HA; Teerlink T; Zanen HC
    Dev Biol Stand; 1986; 63():147-52. PubMed ID: 3091433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
    Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
    Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with meningococcal outer-membrane protein vesicles containing lipooligosaccharide protects mice against lethal experimental group B Neisseria meningitidis infection and septic shock.
    Quakyi EK; Frasch CE; Buller N; Tsai CM
    J Infect Dis; 1999 Sep; 180(3):747-54. PubMed ID: 10438363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man.
    Zollinger WD; Mandrell RE; Griffiss JM; Altieri P; Berman S
    J Clin Invest; 1979 May; 63(5):836-48. PubMed ID: 109466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A potential polyvalent Neisseria meningitidis vaccine based on a mixture of CaCl2 cell extracts from groups A, B and Y.
    Bisaillon JG; McSween G; Portelance V; Beaudet R; Morosoli R; Pouliot P; Micusan V
    Microbios; 1989; 60(244-245):193-208. PubMed ID: 2515422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
    Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine.
    Rosenqvist E; Høiby EA; Bjune G; Aase A; Halstensen A; Lehmann AK; Paulssen J; Holst J; Michaelsen TE; Nøkleby H; Frøholm LO; Closs O
    Dev Biol Stand; 1998; 92():323-33. PubMed ID: 9554288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine.
    Rosenqvist E; Høiby EA; Wedege E; Caugant DA; Frøholm LO; McGuinness BT; Brooks J; Lambden PR; Heckels JE
    Microb Pathog; 1993 Sep; 15(3):197-205. PubMed ID: 7505873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outer membrane proteins of Neisseria meningitidis: structure and importance in meningococcal disease.
    Frasch CE; Tsai CM; Mocca LF
    Clin Invest Med; 1986; 9(2):101-7. PubMed ID: 3089660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B.
    Pillai S; Howell A; Alexander K; Bentley BE; Jiang HQ; Ambrose K; Zhu D; Zlotnick G
    Vaccine; 2005 Mar; 23(17-18):2206-9. PubMed ID: 15755596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningococcal group B vaccine trial in Norway 1981--1982. Preliminary report of results available November 1982.
    Frøholm LO; Berdal BP; Bøvre K; Gaustad P; Harboe A; Holten E; Høiby EA; Lystad A; Omland T; Frasch CE
    NIPH Ann; 1983 Dec; 6(2):133-8. PubMed ID: 6427703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meningococcal vaccines.
    Bethell D; Pollard AJ
    Expert Rev Vaccines; 2002 Jun; 1(1):75-84. PubMed ID: 12908514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
    Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
    Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba.
    Sierra GV; Campa HC; Varcacel NM; Garcia IL; Izquierdo PL; Sotolongo PF; Casanueva GV; Rico CO; Rodriguez CR; Terry MH
    NIPH Ann; 1991 Dec; 14(2):195-207; discussion 208-10. PubMed ID: 1812432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No evidence for serosubtype-restricted protection among teenagers vaccinated with the Norwegian group B outer membrane vesicle vaccine.
    Wedege E; Nokleby H; Bjune G
    J Infect Dis; 1999 Jul; 180(1):242; author reply 242-3. PubMed ID: 10353890
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of meningococcal outer membrane protein vaccines solubilized with detergent or C polysaccharide.
    Poolman JT; Timmermans HA; Hopman CT; Teerlink T; Van Vught PA; Witvliet MH; Beuvery EC
    Antonie Van Leeuwenhoek; 1987; 53(6):413-9. PubMed ID: 3130780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci.
    Jolley KA; Appleby L; Wright JC; Christodoulides M; Heckels JE
    Infect Immun; 2001 Jun; 69(6):3809-16. PubMed ID: 11349046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development.
    Saukkonen K; Abdillahi H; Poolman JT; Leinonen M
    Microb Pathog; 1987 Oct; 3(4):261-7. PubMed ID: 3143885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease.
    Fredriksen JH; Rosenqvist E; Wedege E; Bryn K; Bjune G; Frøholm LO; Lindbak AK; Møgster B; Namork E; Rye U
    NIPH Ann; 1991 Dec; 14(2):67-79; discussion 79-80. PubMed ID: 1812438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.